Aubrey Capital Management Ltd raised its holdings in shares of HealthEquity, Inc. (NASDAQ:HQY - Free Report) by 40.4% in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 36,500 shares of the company's stock after buying an additional 10,500 shares during the period. HealthEquity comprises 1.4% of Aubrey Capital Management Ltd's portfolio, making the stock its 24th largest holding. Aubrey Capital Management Ltd's holdings in HealthEquity were worth $3,823,000 as of its most recent SEC filing.
A number of other hedge funds and other institutional investors have also added to or reduced their stakes in HQY. GAMMA Investing LLC increased its holdings in HealthEquity by 25.9% during the first quarter. GAMMA Investing LLC now owns 1,571 shares of the company's stock valued at $139,000 after buying an additional 323 shares during the last quarter. SG Americas Securities LLC increased its holdings in HealthEquity by 7.1% during the first quarter. SG Americas Securities LLC now owns 5,843 shares of the company's stock valued at $516,000 after buying an additional 388 shares during the last quarter. Fifth Third Bancorp increased its holdings in HealthEquity by 17.5% during the first quarter. Fifth Third Bancorp now owns 955 shares of the company's stock valued at $84,000 after buying an additional 142 shares during the last quarter. Wealth Enhancement Advisory Services LLC increased its holdings in HealthEquity by 24.7% during the first quarter. Wealth Enhancement Advisory Services LLC now owns 6,380 shares of the company's stock valued at $564,000 after buying an additional 1,265 shares during the last quarter. Finally, Janney Montgomery Scott LLC increased its holdings in HealthEquity by 17.3% during the first quarter. Janney Montgomery Scott LLC now owns 6,276 shares of the company's stock valued at $555,000 after buying an additional 924 shares during the last quarter. 99.55% of the stock is owned by hedge funds and other institutional investors.
Insider Buying and Selling at HealthEquity
In related news, EVP Michael Henry Fiore sold 1,781 shares of the firm's stock in a transaction on Tuesday, October 7th. The shares were sold at an average price of $88.21, for a total transaction of $157,102.01. Following the completion of the transaction, the executive vice president directly owned 49,795 shares of the company's stock, valued at approximately $4,392,416.95. This trade represents a 3.45% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, EVP Delano Ladd sold 6,000 shares of the firm's stock in a transaction on Friday, September 19th. The shares were sold at an average price of $94.11, for a total transaction of $564,660.00. Following the transaction, the executive vice president directly owned 79,456 shares of the company's stock, valued at $7,477,604.16. The trade was a 7.02% decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 1.50% of the company's stock.
HealthEquity Stock Performance
HQY opened at $91.04 on Friday. The stock has a market capitalization of $7.84 billion, a price-to-earnings ratio of 55.18, a PEG ratio of 1.33 and a beta of 0.47. The company has a fifty day moving average of $91.73 and a 200 day moving average of $93.96. HealthEquity, Inc. has a fifty-two week low of $74.07 and a fifty-two week high of $116.65. The company has a debt-to-equity ratio of 0.47, a quick ratio of 4.23 and a current ratio of 4.23.
HealthEquity (NASDAQ:HQY - Get Free Report) last posted its earnings results on Tuesday, September 2nd. The company reported $0.92 earnings per share for the quarter, meeting the consensus estimate of $0.92. The company had revenue of $325.80 million during the quarter, compared to analysts' expectations of $320.68 million. HealthEquity had a net margin of 11.49% and a return on equity of 12.04%. HealthEquity has set its FY 2026 guidance at 3.740-3.91 EPS. As a group, sell-side analysts forecast that HealthEquity, Inc. will post 2.32 earnings per share for the current fiscal year.
Wall Street Analysts Forecast Growth
HQY has been the subject of a number of research reports. Jefferies Financial Group upped their target price on shares of HealthEquity from $130.00 to $134.00 and gave the company a "buy" rating in a report on Wednesday, September 3rd. Raymond James Financial reissued a "strong-buy" rating and issued a $120.00 price objective (up from $115.00) on shares of HealthEquity in a research note on Tuesday, July 8th. Barrington Research reissued an "outperform" rating and issued a $125.00 price objective on shares of HealthEquity in a research note on Friday, August 29th. JPMorgan Chase & Co. increased their price objective on shares of HealthEquity from $125.00 to $126.00 and gave the stock an "overweight" rating in a research note on Wednesday, September 3rd. Finally, Weiss Ratings reissued a "hold (c+)" rating on shares of HealthEquity in a research note on Wednesday, October 8th. One investment analyst has rated the stock with a Strong Buy rating, eleven have issued a Buy rating and two have given a Hold rating to the company's stock. Based on data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average price target of $121.31.
Check Out Our Latest Stock Report on HealthEquity
About HealthEquity
(
Free Report)
HealthEquity, Inc provides technology-enabled services platforms to consumers and employers in the United States. The company offers cloud-based platforms for individuals to make health saving and spending decisions, pay healthcare bills, receive personalized benefit information, earn wellness incentives, grow their savings, and make investment choices; and health savings accounts.
Featured Stories
Want to see what other hedge funds are holding HQY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for HealthEquity, Inc. (NASDAQ:HQY - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider HealthEquity, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and HealthEquity wasn't on the list.
While HealthEquity currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.